Bristol Myers Squibb (BMY) Suffers a Larger Drop Than the General Market: Key Insights

In the latest close session, Bristol Myers Squibb (BMY) was down 2.4% at $55.26. This move lagged the S&P 500's daily loss of 0.06%. On the other hand, the Dow registered a loss of 0.17%, and the technology-centric Nasdaq decreased by 0.06%. Prior to today's trading, shares of the biopharmaceutical company had gained 6.17% outpaced the Medical sector's loss of 0.79% and the S&P 500's gain of 1.99%.Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on February 5, 2026. The company is expected to report EPS of $1.6, down 4.19% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $12.28 billion, indicating a 0.49% downward movement from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.48 per share and revenue of $47.91 billion. These totals would mark changes of +463.48% and 0%, respectively, from last year. It is also important to note the recent changes to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.38% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb is currently a Zacks Rank #3 (Hold). From a valuation perspective, Bristol Myers Squibb is currently exchanging hands at a Forward P/E ratio of 9.38. For comparison, its industry has an average Forward P/E of 19.55, which means Bristol Myers Squibb is trading at a discount to the group. It's also important to note that BMY currently trades at a PEG ratio of 9.38. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BMY's industry had an average PEG ratio of 1.48 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 98, finds itself in the top 40% echelons of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks